Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 32Leukemia 21Lymphoma 15Prostatic Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 10Lymphoma, Large B-Cell, Diffuse 9Leukemia, Monocytic, Acute 8Recurrence 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia, Erythroblastic, Acute 7Congenital Abnormalities 7Myelodysplastic Syndromes 6Leukemia, Megakaryoblastic, Acute 6Lymphoma, Large-Cell, Immunoblastic 5Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Blast Crisis 4Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2HIV Infections 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Imatinib Mesylate 8Dasatinib 4Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2Prednisone 2Daunorubicin 2Cyclophosphamide 2venetoclax 1ponatinib 1olverembatinib 1flumatinib 1bosutinib 1blinatumomab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mercaptopurine 1Interferons 1Inotuzumab Ozogamicin 1Etoposide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Philadelphia Chromosome × Mitoxantrone × Clear all
NCT02523976 2026-02-11

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡